Retatrutide Shows 33% Weight Loss With Muscle Sparing as Experts Warn on Unregulated Supply
Updated
Updated · Fox News · May 20
Retatrutide Shows 33% Weight Loss With Muscle Sparing as Experts Warn on Unregulated Supply
1 articles · Updated · Fox News · May 20
Retatrutide, an investigational obesity drug, was highlighted as a potential advance because trial results discussed by Andrew Huberman suggest users can lose up to one-third of body weight over about a year while preserving more lean muscle.
The drug differs from earlier GLP-1 therapies by acting on 3 hormone pathways—GLP-1, GIP and glucagon—which Huberman said may spread the effect more subtly and lower side effects tied to rapid calorie deficits.
That promise is colliding with a growing gray market: Huberman warned online peptide sellers and compounding sources may contain impurities despite claims of 99% purity, including bacterial toxins such as LPS that can drive inflammation over repeated injections.
Lilly says retatrutide is legally available only through its clinical trials, and the drug has not been approved by any regulator, prompting experts to urge patients to avoid any product sold outside supervised studies.
With approval still years away, what are the dangers of the booming online market for 'quick-fix' weight-loss peptides?
If this new drug isn't a magic bullet, what is the real key to preserving muscle during major weight loss?
When the injections stop, how can patients prevent the seemingly inevitable weight regain?
Retatrutide and the Future of Weight Loss: Unprecedented 15–24% Efficacy, Safety, and the Risks of Unregulated Use
Overview
Retatrutide, an investigational drug developed by Eli Lilly, is attracting significant attention for its promising potential in weight management. Although not yet approved for human use as of May 2026, clinical trials have shown encouraging tolerability, with relatively low discontinuation rates. The drug’s reputation is growing rapidly on social media, leading some individuals to buy unregulated powders labeled 'reta' or 'ret' from research labs online. This trend is part of a broader 'GLP-1 boom,' raising immediate safety concerns as people seek out new weight loss solutions before official approval and oversight are in place.